a biotech in the birth....with $24 million to spen, page-2

This company is probably going down the same track as Circadian Technologies and Biotech Capital.The company's principal activities will probably include the management and funding of pharmaceutical research and development projects with Australian and New Zealand Universities to the stage where the Company seeks collaborative and/or licensing arrangements with major international pharmaceutical companies. These activities may also include investment in leading edge Australian technology. The company will is look for innovation, management and commercialisation of projects and technology investments.
EQITX will seek to minimise the inherent risk associated with investing in such companies by investing across a diverse portfolio of these types of companies. They will probably invest in 10-20 companies with a typical investment size in the order of $2,000,000 up to $4,000,000.
The Company will spread its investments from early stage up to and including pre-IPO and placement opportunities. The aim will be to have a broad spectrum of investment maturities ensuring a steady stream of "liquidity events" as projects reach IPO status.
This strategy has paid off in the past for CIR and BTC and with this management,likely to succeed with EQX.